Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation.

Archive ouverte

Gagelmann, Nico | Eikema, Diderik-Jan | Stelljes, Matthias | Beelen, Dietrich | de Wreede, Liesbeth C. | Mufti, Ghulam | Knelange, Nina Simone | Niederwieser, Dietger | Friis, Lone S | Ehnninger, Gerhard | Nagler, Arnon | Yakoub-Agha, Ibrahim | Meijer, Ellen | Ljungman, Per | Maertens, Johan | Kanz, Lothar | Lopez-Corral, Lucia | Brecht, Arne | Craddock, Charles | Finke, Jurgen | Cornelissen, Jan J | Bernasconi, Paolo | Chevallier, Patrice | Sierra, Jorge | Robin, Marie | Kroger, Nicolaus

Edité par CCSD ; Ferrata Storti Foundation -

International audience. The aim of this study was to develop and validate a clinical and transplant-specific prognostic score using data from a large cohort of patients with myelodysplastic syndromes reported to the European Society for Blood and Marrow Transplantation registry. A Cox model was fitted to detect clinical and transplant-related variables prognostic of outcome. Then, cross-validation was performed to evaluate the validity and consistency of the model. Seven independent risk factors for survival were identified: age ≥50 years, matched unrelated donor, Karnofsky Performance Status <90%, very poor cytogenetics or monosomal karyotype, positive cytomegalovirus status of the recipient, blood blasts >1%, and platelet count ≤50 × 10/L prior to transplantation. Incorporating these factors into a four-level risk score yielded hazard ratios for death, with low-risk (score of 0-1) as reference, of 2.02 (95% CI: 1.41-2.90) for the intermediate-risk group (score of 2-3), 3.49 (95% CI: 2.45-4.97) for the high-risk group (score of 4-5), and 5.90 (95% CI: 4.01-8.67) for the very high-risk group (score of >5). The score was predictive of survival, relapse-free survival, relapse, and non-relapse mortality (<0.001, respectively). Cross-validation yielded significant and reproducible improvement in prognostic ability with C-statistics being 0.609 (95% CI: 0.588-0.629) 0.555 for the registry and 0.579 for the Center for Blood and Marrow Transplant Research registry. Prediction was even further augmented after applying a nomogram using age and platelets as continuous variables showing C-statistics of 0.628 (95% CI: 0.616-0.637). In conclusion, compared to existing prognostic systems, this proposed transplant-specific risk score offers improved performance with respect to post-transplant risk stratification in myelodysplastic syndromes.

Suggestions

Du même auteur

Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia.

Archive ouverte | Schetelig, Johannes | CCSD

International audience. The causes and rates of late patient-mortality following alloHCT for myelodysplastic syndromes or secondary acute myeloid leukemia were studied, to assess the contribution of relapse-related,...

Comparison of dipss and mysec-pm for prediction of outcome in post-pv and et myelofibrosis after allogeneic stem-cell transplantation

Archive ouverte | Gagelmann, Nico | CCSD

International audience. We aimed to validate the MYelofibrosis SECondary to PV and ET prognostic model (MYSEC-PM) in 159 patients with myelofibrosis secondary to polycythemia vera (PV) and essential thrombocythemia ...

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis

Archive ouverte | Robin, Marie | CCSD

International audience. Allogeneic hematopoietic stem cell transplant remains the only curative treatment for myelofibrosis. Most post-transplantation events occur during the first two years and hence we aimed to an...

Chargement des enrichissements...